Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.89 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.73 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.62 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668488 | 0.96 | HPGD (0.96) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL19703413 | 0.94 | HPGD (1.00) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL1300190 | 0.94 | HPGD (1.00) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL29675219 | 0.92 | GAA (0.85) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL10055001 | 0.92 | GAA (0.85) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL501924 | 0.92 | GAA (0.85) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL25730750 | 0.91 | HPGD (0.87) | HPGDMAPTMEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL1804763 | 0.90 | GAA (0.82) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL31401950 | 0.89 | HPGD (0.83) | HPGDMAPTMEN1KMT2AGAA | |
| SCHEMBL19501631 | 0.88 | HPGD (0.87) | HPGDMAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057964-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | claimed |
| EP-2261203-B1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARING PROCESSES AND THE USES THEREOF | BEIJING YINGU CENTURY PHARMACY CO LTD (CN) | 2016-05-25 | — | — | EP | claimed |
| WO-2015057659-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | claimed |
| US-8673981-B2 | Phenylcyclobutylamide derivatives and their stereoisomers, the preparation processes and uses thereof | YinGu Pharmaceutical Co., Ltd (CN) | 2014-03-18 | — | — | US | claimed |
| US-20130289124-A1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARATION PROCESSES AND USES THEREOF | YinGu Pharmaceutical Co., Ltd (CN) | 2013-10-31 | — | — | US | claimed |
| US-8497305-B2 | Phenylcyclobutylamide derivatives and their stereoisomers, the preparation processes and uses thereof | YinGu Pharmaceutical Co., Ltd (CN) | 2013-07-30 | — | — | US | claimed |
| US-20110224305-A1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARATION PROCESSES AND USES THEREOF | BEIJING YINGU CENTURY PHARMACY CO. LTD (CN) | 2011-09-15 | — | — | US | claimed |
| EP-2261203-A1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARING PROCESSES AND THE USES THEREOF | Beijing Cachet Biomedical Co., Ltd (CN) | 2010-12-15 | — | — | EP | claimed |
| CN-116802176-A | Oxindoles and methods of use thereof | 阿利戈斯治疗公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-2261203-A1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARING PROCESSES AND THE USES THEREOF | Beijing Cachet Biomedical Co., Ltd (CN) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261203-A1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARING PROCESSES AND THE USES THEREOF | Beijing Cachet Biomedical Co., Ltd (CN) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009124458-A1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARING PROCESSES AND THE USES THEREOF | 北京嘉事堂生物医药有限公司 (CN) | 2009-10-15 | — | — | WO | disclosed |
| EP-1490043-A4 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1490043-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082190-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | HPGD 2419/4885MAPT 3053/4885MEN1 4044/4885 |
| US-20110224305-A1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARATION PROCESSES AND USES THEREOF | AADAC, WIZ, CEBPZ | HPGD 2587/4885MAPT 1887/4885MEN1 4756/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | HPGD 2239/4885MAPT 2752/4885MEN1 2671/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | HPGD 2419/4885MAPT 3053/4885MEN1 4044/4885 |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | HPGD 2419/4885MAPT 3053/4885MEN1 4044/4885 |
| US-20130289124-A1 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARATION PROCESSES AND USES THEREOF | AADAC, WIZ, CEBPZ | HPGD 2587/4885MAPT 1887/4885MEN1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.